US Patent

US8889159 — Compositions and methods for treating hepatitis C virus

Method of Use · Assigned to Gilead Pharmasset LLC · Expires 2029-03-26 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a composition and method for treating hepatitis C virus infection using GS-7977 and ribavirin.

USPTO Abstract

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-2040 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —

Patent Metadata

Patent number
US8889159
Jurisdiction
US
Classification
Method of Use
Expires
2029-03-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Gilead Pharmasset LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.